Search

everythinglearnresearchcommunity

for

Search:↓

Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.

Low iron, low thyroid function, and stress are linked to excessive hair shedding in women.

The report suggests that hair loss in Cronkhite-Canada syndrome may be caused by alopecia areata incognita, as shown by a patient's improvement with treatment.

Some drugs can cause hair loss, excessive growth, or color changes, often reversible but sometimes permanent.

Hair loss is caused by genetics and hormones, diagnosed through examination and biopsy, and treated with medications or surgery.

ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.

Diagnosing alopecia areata is challenging and requires careful examination and various tests to distinguish it from other hair loss types.

Certain growth factors affect hair loss in women and could be targeted for treatment.

Some drugs can cause reversible hair loss, but certain chemotherapy drugs may lead to permanent hair loss; drugs can also change hair color and texture.

COVID-19 may trigger sudden temporary hair loss.

Wearing a hijab does not cause hair loss.

About 61% of women who had COVID-19 experienced hair loss afterward.

Psoriasis can cause temporary or permanent hair loss.

Apoptosis is crucial for healthy skin and treating skin diseases.

The most common hair loss type at specialist clinics is androgenetic alopecia, especially in younger men, followed by alopecia areata and telogen effluvium, with differences seen across regions.

Most hair loss in captive rhesus macaques is likely due to environmental and behavioral factors.

Trichodynia is a painful scalp condition linked to hair loss and inflammation, often with anxiety, affecting more women and needing better treatment options.

Skin problems from transplant drugs are common and need careful management in organ transplant patients.

The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.

Emotional stress can trigger intermittent hair loss in chronic telogen effluvium, which may not improve with treatment if stress continues.

Many COVID-19 patients experience temporary hair loss after infection, not linked to infection severity or treatment.

A woman had hair loss, nail changes, and skin peeling after a COVID-19 infection, which got better on their own.

Hair shedding after COVID-19 is more linked to the disease's severity and inflammation rather than hormones, with women at higher risk.

The treatment with an oral drug and topical lotion is effective and well-tolerated for hair loss after COVID-19.

The TrichoScan method effectively measures hair growth and helps choose patients for hair restoration surgery.

Serum ferritin can help diagnose Telogen Effluvium.

Higher cannabis exposure may worsen hair loss.

Trichoscopy is effective for diagnosing hair and scalp disorders without invasive biopsies.

Many people in Saudi Arabia experienced hair loss after COVID-19, especially women, those treated with antivirals, and those with a history of hair shedding.

COVID-19 survivors working in healthcare may experience temporary hair loss.